Substance / Medication

Magnesium oxide

Overview

Active Ingredient
magnesium oxide
RxNorm CUI
6582

Indications

CLENPIQ is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older.

Labeler: Ferring Pharmaceuticals Inc.Updated: 2025-04-04T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

CLENPIQ is contraindicated in the following conditions: Warnings and Precautions (5.3) [see]. Patients with severe renal impairment (creatinine clearance less than 30 mL/minute), which may result in accumulation of magnesium Warnings and Precautions (5.6) [see]. Gastrointestinal obstruction or ileus

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
2
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The effect of preoperative oral magnesium oxide on the severity of postoperative pain among women undergoing hysterectomy.
Hashemian Morteza, Mirkheshti Alireza, Mirafzal Amirhossein et al. · Ir J Med Sci · 2022
PMID: 35022952RCT
Co-administration of Magnesium Oxide Reduces the Serum Concentration of Hydrophobic Basic Drugs in Patients Treated with Antipsychotic Drugs.
Yoshida Hisahiro, Takahashi Minori, Honda Misuzu et al. · Biol Pharm Bull · 2019
PMID: 31155577RCT
A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD.
Sakaguchi Yusuke, Hamano Takayuki, Obi Yoshitsugu et al. · J Am Soc Nephrol · 2019
PMID: 31036759RCTFull text (PMC)
Effect of Magnesium Oxide Supplementation on Nocturnal Leg Cramps: A Randomized Clinical Trial.
Roguin Maor Noga, Alperin Mordechai, Shturman Elena et al. · JAMA Intern Med · 2017
PMID: 28241153RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Magnesium oxide (substance)
SNOMED CT
66389008
UMLS CUI
C0024477
RxNorm CUI
6582
Labeler
Ferring Pharmaceuticals Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.